US 12,453,729 B2
Pharmaceutical formulations
Farhan Abdel Karim Mohammad Al Husban, Cambridge (GB)
Assigned to AstraZeneca AB, Sodertalje (SE)
Filed by AstraZeneca AB, Södertälje (SE)
Filed on Apr. 22, 2021, as Appl. No. 17/237,201.
Claims priority of provisional application 63/014,923, filed on Apr. 24, 2020.
Prior Publication US 2021/0330665 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4745 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01)
CPC A61K 31/4745 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/2095 (2013.01); A61K 9/284 (2013.01); A61K 9/2866 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A pharmaceutical tablet comprising N-(1-(3-fluoropropyl)-azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine, microcrystalline cellulose, and dicalcium phosphate anhydrous; wherein the tablet contains 75 mg of N-(1-(3-fluoropropyl) azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine; and wherein the ratio of microcrystalline cellulose to dicalcium phosphate anhydrous is from 3:1 to 2:3.